(Q38238597)

31 August 2017

MAPK pathway inhibition in melanoma: resistance three ways (English)

1 reference

31 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Claudia Wellbrock

series ordinal

1

1 reference

31 August 2017

1 August 2014

1 reference

Biochemical Society Transactions

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

727-732

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109949%20AND%20SRC:MED&resulttype=core&format=json

BRAF as therapeutic target in melanoma

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Cyclic AMP a key messenger in the regulation of skin pigmentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Cellular senescence in naevi and immortalisation in melanoma: a role for p16?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

PTEN signaling pathways in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

MITF: master regulator of melanocyte development and melanoma oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140020

21 January 2018

Identifiers

DOI

10.1042/BST20140020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109949%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference